TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has officially launched Tiazac(R) XC in Canada.
Tiazac(R) XC is a novel, extended-release formulation of diltiazem hydrochloride that features a new Diffusion Technology (DiTech(TM)) delivery system designed for night-time administration, resulting in improved 24-hour blood-pressure (BP) control with additional BP control during the early morning hours.
The improved release technology in Tiazac(R) XC allows for bedtime administration, thereby targeting the high-risk morning surge in blood pressure that most patients experience. Importantly, bedtime dosing may mitigate some common side effects of diltiazem treatment, as suggested by the fact that the incidence of edema was not statistically different with Tiazac(R) XC, compared with placebo.
Building on the success of Biovail's Tiazac(R), Canada's leading once-daily diltiazem formulation, Biovail's 80-member Canadian sales team is fully trained and well prepared to discuss with physicians and pharmacists the benefits of Tiazac(R) XC in the effective treatment of hypertension.
In addition to physician calls to introduce Tiazac(R) XC, launch elements include sampling, marketing and other promotional activities.
About TIAZAC(R) XC
Tiazac(R) XC (diltiazem HCl) is indicated for the treatment of high blood pressure (hypertension). Tiazac(R) XC is a brand name for once-daily, extended-release tablet formulations for bedtime administration in dosages of 180 mg-360 mg per day. Tiazac(R) XC works by slowing the heart rate, and by relaxing and widening blood vessels (arteries), which reduces blood pressure. Widening of the coronary arteries also increases the amount of blood reaching the heart. Tiazac(R) XC belongs to a class of anti-hypertensive drugs known as non-dihydropyridine calcium channel blockers (CCBs).
About Biovail Corporation
Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. For more information about Biovail, visit the company's Web site at www.biovail.com
For further information, please contact Ken Howling at 905-286-3000 or send inquiries to firstname.lastname@example.org.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and Drug Administration ("FDA") and Canadian Therapeutic Products Directorate ("TPD") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission ("SEC") and the Ontario Securities Commission ("OSC"). Biovail Corporation undertakes no obligation to update or revise any forward-looking statement.
COPYRIGHT 2005 Business Wire
COPYRIGHT 2005 Gale Group